Chimeric Antigen Receptor Car T Cell Immunotherapy Competitive Landscape Pipeline And Market Analysis

"Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2018", report provides comprehensive Insight about marketed and pipeline drugs across this Immunotherapy. The report provides the detailed analysis of 190+ products along with 60+ companies involved. Celgene Corporation and bluebird bio has been granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for bb2121 Anti-BCMA CAR-T Cell Therapy for Relapsed and Refractory Multiple Myeloma.

Products covered by Phase

  • Phase II, Phase I and IND
  • Pre-clinical and Discovery

Overview of pipeline development activities for Chimeric Antigen Receptor (CAR) T cell Immunotherapy

Pipeline analysis of 190+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.

Therapeutic segmentation of products for Chimeric Antigen Receptor (CAR) T cell Immunotherapy

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.


Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.


  • The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy and also provide company profiling
  • Pipeline products coverage based on various stages of development ranging from mid stage till discovery stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy

  • Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
  • Establish a comprehensive understanding of the current pipeline scenario across Chimeric Antigen Receptor (CAR) T cell Immunotherapy to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Chimeric Antigen Receptor (CAR) T cell Immunotherapy R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Devise corrective measures for pipeline projects by understanding Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline depth and focus of Indication therapeutics
  • Developing strategic initiatives to support your drug development activities
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Chimeric Antigen Receptor (CAR) T cell Immunotherapy to enhance and expand business potential and scope
  • Provides strategically significant competitor information, analysis, and Insight to formulate effective R&D development strategies
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs
  • Gaining a full picture of the Competitive Landscape for Evidence based Decisions


Chimeric antigen receptor (CAR) T-cells


CARs and Generations

Advantages of CAR-T cells

Adverse Events with CAR T-cell Therapy

Limitations of Existing Technologies for CAR T-Cells

Marketed Products

Kymriah: Novartis

Product Description

Regulatory Milestones

Research and Development

Other Clinical Activities

Product Development Activities

Pipeline Therapeutics

Clinical Phase Products

Non-Clinical Phase Products

Competitive Landscape

Comparative Analysis

Mid Stage Products (Phase II)

Comparative Analysis

AU105: Aurora BioPharma

Product Description

Research and Development

Product Development Activities

(The list continues)

Early Stage Products (Phase I)

Comparative Analysis

IND Stage Products

Comparative Analysis

Unknown Stage Products

Comparative Analysis

Pre-clinical and Discovery Products

Comparative Analysis

Therapeutic Assessment : Clinical Phase Products

Assessment by Route of Administration

Assessment by Stage and Route of Administration


Table 1: CARs Generations

Table 2: CARs Generations-Associated Target Antigens and Indications

Table 3: Total Products for CART Cell therapy

Table 4: Mid Stage Products (Phase II)

Table 5: Early Stage Products (Phase I)

Table 6: IND Stage Products

Table 7: Unknown Stage Products

Table 8: Pre-clinical Stage Products

Table 9: Discovery Stage Products

Table 10: Assessment by Route of Administration

Table 11:: Assessment by Stage and Route of Administration

Figure 1: Total Products for CART Cell therapy

Figure 2: Mid Stage Products (Phase II)

Figure 3: Early Stage Products (Phase I)

Figure 4: IND Stage Products

Figure 5: Unknown Stage Products

Figure 6: Pre-clinical and Discovery Stage Products

Figure 7: Assessment by Route of Administration

Figure 8: Assessment by Stage and Route of Administration

Aikang Biomedical Technology


Aurora BioPharma


Avacta Life Sciences

Beijing Biohealthcare Biotechnology

Beijing Doing Biomedical

Beijing Immunochina Medical Science & Technology

Beijing Pregene Science and Technology Company

Beijing Sanwater Biological Technology

Bellicum Pharmaceuticals

Benitec Biopharma

bluebird bio

CARMA Therapeutics

Carsgen Therapeutics


Cellular Biomedicine Group


Chimeric Therapeutics

CRISPR Therapeutics


Eureka Therapeutics

Fate Therapeutics

Formula Pharmaceuticals

Fortress Biotech

Gilead Sciences


Guangdong Zhaotai InVivo Biomedicine

Hebei Senlang Biotechnology

Helix BioPharma


iCell Gene Therapeutics

Innovative Cellular Therapeutics

Intellia Therapeutics

Juno Therapeutics

Kite Pharma

MabVax Therapeutics

Marino Biotechnology




Mustang Bio (subsidiary of Fortress Biotech)

Nanjing Legend Biotech

Noile-Immune Biotech



Oncternal Therapeutics

Oxford Biomedica

Persongen Biomedicine (Suzhou)

Poseida Therapeutics



Shanghai GeneChem

Shanghai Unicar-Therapy Bio-medicine Technology


Sinobioway Cell Therapy

Sorrento Therapeutics


Takara Bio

Tessa Therapeutics

TILT Biotherapeutics

Tmunity Therapeutics

Wuhan Sian Medical Technology

Zhongyuan Union Stem Cell Bioengineering

Ziopharm Oncology

  • Tags:
  • Chimeric Antigen Receptor (CAR) T c...

Forward to Friend

Need A Quote